Non-randomized open trial of eicosapentaenoic acid (EPA), an omega-3 fatty acid, in ten people with chronic epilepsy

Epilepsy and Behavior

Volumn 23, Issue 3, 2012, Pages 370-372

  Yuen, Alan W C ^a,f   Flugel, Dominique ^b   Poepel, Annkathrin ^c   Bell, Gail S ^a,f   Peacock, Janet L ^d   Sander, Josemir W ^a,e,f  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b EPILEPSY SOCIETY   (United Kingdom)

^c CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^d SWISS EPILEPSY CENTER   (Switzerland)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

Author keywords

Clinical trial; Eicosapentaenoic acid; EPA; Epilepsy; Omega 3 fatty acids; Supplementation

Indexed keywords

ANTICONVULSIVE AGENT; ICOSAPENTAENOIC ACID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIET SUPPLEMENTATION; DISEASE SEVERITY; EPILEPSY; EXPLORATORY RESEARCH; FEMALE; HUMAN; MALE; OPEN STUDY; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; ANTICONVULSANTS; CHRONIC DISEASE; DIETARY SUPPLEMENTS; EICOSAPENTAENOIC ACID; EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84858280318     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2011.11.030     Document Type: Article

References (13)

1. Taha A.Y., Burnham W.M., Auvin S. Polyunsaturated fatty acids and epilepsy. Epilepsia 2010, 51(8):1348-1358.
2. Yuen A.W., Sander J.W., Fluegel D., et al. Omega-3 fatty acid supplementation in patients with chronic epilepsy: a randomized trial. Epilepsy Behav 2005, 7(2):253-258.
3. Fraser D.D., Whiting S., Andrew R.D., Macdonald E.A., Musa-Veloso K., Cunnane S.C. Elevated polyunsaturated fatty acids in blood serum obtained from children on the ketogenic diet. Neurology 2003, 60(6):1026-1029.
4. Horrobin D.F., Jenkins K., Bennett C.N., Christie W.W. Eicosapentaenoic acid and arachidonic acid: collaboration and not antagonism is the key to biological understanding. Prostaglandins Leukot Essent Fatty Acids 2002, 66(1):83-90.
5. Dahlin M., Hjelte L., Nilsson S., Amark P. Plasma phospholipid fatty acids are influenced by a ketogenic diet enriched with n-3 fatty acids in children with epilepsy. Epilepsy Res 2007, 73(2):199-207.
6. Porta N., Vallee L., Boutry E., et al. Comparison of seizure reduction and serum fatty acid levels after receiving the ketogenic and modified Atkins diet. Seizure 2009, 18(5):359-364.
7. Peet M., Horrobin D.F. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 2002, 59(10):913-919.
8. Peet M., Horrobin D.F. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res 2002, 36(1):7-18.
9. Puri B.K., Bydder G.M., Counsell S.J., et al. MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment. Neuroreport 2002, 13(1):123-126.
10. Peet M., Brind J., Ramchand C.N., Shah S., Vankar G.K. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res 2001, 49(3):243-251.
11. Marangell L.B., Martinez J.M., Zboyan H.A., Kertz B., Kim H.F., Puryear L.J. A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am J Psychiatry 2003, 160(5):996-998.
12. Puri B.K., Richardson A.J., Horrobin D.F., et al. Eicosapentaenoic acid treatment in schizophrenia associated with symptom remission, normalisation of blood fatty acids, reduced neuronal membrane phospholipid turnover and structural brain changes. Int J Clin Pract 2000, 54(1):57-63.
13. Anhut H., Ashman P., Feuerstein T.J., Sauermann W., Saunders M., Schmidt B. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. The International Gabapentin Study Group. Epilepsia 1994 Jul, 35(4):795-801.